Bone marrow transplantation and thymopoietin pentapeptide treatment in two infants with immunodeficiency with predominant T-cell defects

Luisa Businco, P. Rossi, R. Paganelli, Elena Galli, G. DiGilio, Patrizia Lulli, F. Aiuti

Research output: Contribution to journalArticle


Two infants with immunodeficiency with predominant T-cell defects received transplants of HLA-identical bone marrow cells along with thymopoietin pentapeptide (TP-5) treatment and no prior immunosuppressive therapy. Both patients achieved durable engraftment with early reconstitution of cell-mediated immunity. The study of cell surface antigens with monoclonal antibodies (MoAb) revealed that the early appearance of T-cell subsets defined by OKT4 and OKT8 MoAb occurred. Neither of the patients showed any signs or symptoms of graft versus host disease over a 1-year period. This experience suggests that patients with T-cell deficiency who do not benefit from thymic hormones alone can be successfully treated by bone marrow transplantation. The association of TP-5 with bone marrow transplantation seems to induce and early and stable reconstitution and to protect against fatal post-transplant infection.

Original languageEnglish
Pages (from-to)123-130
Number of pages8
JournalClinical Immunology and Immunopathology
Issue number1
Publication statusPublished - 1984


ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this